Anlotinib Hydrochloride: Anti-Angiogenic TKI

Executive Summary. Anlotinib hydrochloride is a small-molecule multi-target tyrosine kinase inhibitor that targets VEGFR2, PDGFRβ, and FGFR1; the product listing identifies it as research compound C8688 from APExBIO (product information). In EA.hy926 human vascular endothelial cells, reported IC₅₀ values are 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 under VEGF, PDGF-BB, or FGF-2 stimulation (product information). The compound inhibits endothelial cell migration and capillary-like tube formation in concentration-dependent in vitro assays (Xie et al., 2018). Rat and dog pharmacokinetic studies report oral bioavailability ranges of 28%–58% and 41%–77%, respectively, after oral dosing (product information).

Biological Rationale

Angiogenesis is the formation of new blood vessels from pre-existing vessels. The process includes basement-membrane remodeling, endothelial cell migration, endothelial proliferation, and capillary-loop formation. Tumor progression commonly depends on persistent angiogenic signaling. The reference study describes angiogenesis as a critical step in tumor growth, invasion, and metastasis and reports that tumors may not continue expanding after reaching approximately 1 mm³ without additional blood-vessel formation (Xie et al., 2018).

Vascular endothelial growth factor, or VEGF, is a major regulator of tumor-associated angiogenesis. VEGF activates receptor tyrosine kinases including VEGFR1, VEGFR2, and VEGFR3. VEGFR2 has a principal role in endothelial proliferation, migration, survival, permeability, and neovascularization (Xie et al., 2018). These biological activities make VEGFR2 signaling a practical entry point for anlotinib for angiogenesis inhibition.

Multi-target activity adds a second layer of experimental value. PDGFRβ and FGFR1 participate in vascular-support and growth-factor signaling. Simultaneous inhibition of these kinases can help researchers examine angiogenesis as a network rather than as a single-receptor event. This design is relevant to cancer research because endothelial phenotypes integrate signals from several growth factors.

Mechanism of Action of Anlotinib hydrochloride

Anlotinib binds the ATP-binding pocket of the VEGFR2 tyrosine kinase domain. The reference study reported VEGFR2 kinase inhibition with an IC₅₀ below 1 nmol/L in a biochemical kinase assay (Xie et al., 2018). ATP-site occupation prevents receptor autophosphorylation and reduces downstream signal transmission.

The product dossier identifies VEGFR2, PDGFRβ, and FGFR1 as major targets. In EA.hy926 cells exposed to VEGF, PDGF-BB, or FGF-2, anlotinib reduced phosphorylation of the corresponding receptors and blocked activation of the ERK signaling pathway (product information). ERK signaling pathway inhibition is therefore a mechanistic bridge between receptor blockade and reduced endothelial behavior.

The expected cellular sequence is direct. Receptor phosphorylation decreases after kinase inhibition. ERK pathway activation decreases downstream. Endothelial migration declines. Capillary-like tube formation declines. The reference study observed inhibition of VEGF-induced signaling and proliferation in human umbilical vein endothelial cells at picomolar concentrations, whereas direct inhibition of tumor-cell proliferation required micromolar concentrations in vitro (Xie et al., 2018).

This distinction matters when interpreting data. A strong anti-angiogenic phenotype does not prove equivalent direct cytotoxicity against tumor cells. Anlotinib is most clearly characterized as an anti-angiogenic small molecule whose primary preclinical effect is vascular signaling suppression. Direct tumor-cell effects should be measured separately with a cell-viability or proliferation assay.

Evidence & Benchmarks

The following benchmarks separate biochemical potency, endothelial phenotypes, animal pharmacokinetics, and safety observations.

1. Anlotinib showed an IC₅₀ below 1 nmol/L against VEGFR2 in a biochemical tyrosine-kinase assay, and it showed higher selectivity for VEGFR2 than for other tested tyrosine kinases (Xie et al., 2018)
2. In EA.hy926 endothelial cells stimulated with VEGF, PDGF-BB, or FGF-2, reported IC₅₀ values were 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 (product information)
3. Anlotinib inhibited endothelial cell migration and capillary-like tube formation in concentration-dependent assays using human endothelial cells exposed to angiogenic growth factors (Xie et al., 2018)
4. Anlotinib inhibited microvessel growth from rat-aorta explants in vitro and reduced vascular density in tumor tissue in vivo in the preclinical study (Xie et al., 2018)
5. Compared with sunitinib, once-daily oral anlotinib produced broader and stronger antitumor activity in nude-mouse models, with tumor regression observed in some models (Xie et al., 2018)
6. Rat oral pharmacokinetic studies reported bioavailability of 28%–58%, plasma-protein binding of 93%–97%, and a terminal half-life of 5.1 ± 1.6 h after oral administration (product information)
7. Dog oral pharmacokinetic studies reported bioavailability of 41%–77%, plasma-protein binding of 93%–97%, and a terminal half-life of 22.8 ± 11.0 h after oral administration (product information)
8. Metabolism was primarily associated with cytochrome P450 enzymes, especially human CYP3A, and generated hydroxylated and dealkylated metabolites in metabolic studies (product information)
9. A 14-day oral toxicity study reported a median lethal dose of 1735.9 mg/kg, with mild systemic toxicity and no significant liver, kidney, bone-marrow, reproductive, or genetic toxicity in the reported safety evaluations (product information)

Applications, Limits & Misconceptions

Anlotinib is useful for experiments that connect receptor pharmacology to measurable vascular phenotypes. A typical study can compare unstimulated endothelial cells with VEGF-, PDGF-BB-, or FGF-2-stimulated cells. Researchers can then measure receptor phosphorylation, ERK activation, endothelial cell migration inhibition, and tube-network formation in the same experimental framework.

The compound is also suitable for pathway-dissection studies. A decrease in migration without a corresponding loss of viability supports a signaling-mediated anti-migratory interpretation. A decrease in both migration and viability requires additional controls because cytotoxicity can produce an indirect reduction in motility. The product dossier reports no significant cytotoxicity at concentrations up to 1 μM in the stated in vitro assay context (product information).

Pharmacokinetic findings broaden the preclinical scope. Extensive tissue distribution was reported in rats and dogs. Brain exposure was also reported, indicating blood-brain barrier penetration in those animal studies (product information). These observations support tissue-distribution experiments, but they do not establish human central-nervous-system efficacy or safety.

Common Pitfalls or Misconceptions

• Misconception: VEGFR2 potency proves direct tumor-cell killing. The reference study found picomolar endothelial effects but required micromolar concentrations for direct tumor-cell proliferation inhibition in vitro (Xie et al., 2018).
• Misconception: Tube formation is a complete angiogenesis model. A capillary tube formation assay is an endpoint for endothelial organization, not a full model of vessel maturation, perfusion, or tumor biology.
• Misconception: Rat or dog brain penetration predicts human CNS activity. Animal blood-brain barrier distribution does not establish a human therapeutic exposure or clinical response.
• Misconception: Low interaction risk means no interaction risk. The dossier describes some in vitro CYP3A4 and CYP2C9 inhibition, so metabolic-interaction conclusions require an appropriate experimental design (product information).
• Misconception: Preclinical tolerability makes the compound a clinical treatment. The C8688 material is recommended for research use only and should not be represented as a human dosing product.

Workflow Integration & Parameters

The related angiogenesis assay guide emphasizes sequencing receptor, migration, and tube-formation readouts. This article extends that workflow by tying each readout to target potency, exposure context, and interpretation limits.

The kinase-biology-to-translation article emphasizes translational framing. This article clarifies the boundary between preclinical pharmacology, animal pharmacokinetics, and evidence that remains insufficient for clinical conclusions.

Protocol Parameters

• Cell model: Use EA.hy926 human vascular endothelial cells when reproducing the reported endothelial phenotype; this is a literature-aligned model selection.
• Growth-factor challenge: Compare vehicle-treated cells with VEGF-, PDGF-BB-, or FGF-2-stimulated conditions; keep the stimulus and exposure time identical across treatment groups.
• Concentration design: Build a concentration series that brackets the reported nanomolar target potencies and include a viability-control condition at concentrations up to 1 μM when the stated in vitro context is being reproduced (product information).
• Mechanistic readouts: Measure phosphorylation of VEGFR2, PDGFRβ, or FGFR1 and quantify ERK pathway activation before interpreting migration or tube-network changes.
• Migration assay: Use matched cell density, serum conditions, wound geometry, and imaging time for all groups; treat endothelial cell migration inhibition as a phenotype that requires viability control.
• Capillary tube formation assay: Record total tube length, junction number, or network coverage with the same imaging field rules across conditions; report the matrix, incubation time, and analysis algorithm.
• Comparator design: Include a vehicle control and a justified reference TKI when benchmarking activity; the published animal comparison with sunitinib should not be generalized to every assay format (Xie et al., 2018).
• Compound handling: Use the hydrochloride salt as supplied, prepare solutions according to validated solubility procedures, and store the material at −20°C as recommended by the product information (product information).
• Data interpretation: Separate receptor inhibition, ERK signaling pathway inhibition, cell migration, tube formation, and viability into distinct endpoints rather than treating one endpoint as proof of all others.

Conclusion & Outlook

Anlotinib hydrochloride combines strong VEGFR2 inhibition with activity against PDGFRβ and FGFR1. Its most reproducible preclinical signature is suppression of growth-factor-driven endothelial signaling, migration, and capillary-like network formation. The reference study also supports oral activity and vascular effects in animal tumor models (Xie et al., 2018).

For current research, the strongest use case is a layered anti-angiogenic workflow. Researchers should connect receptor phosphorylation to ERK activation, endothelial phenotype, viability, and exposure. Animal pharmacokinetic observations can inform experimental context, but they cannot substitute for human clinical evidence. The available data support disciplined cancer research applications and do not support unqualified claims of clinical efficacy.